Selection and characterization of human antibody fragments specific for psoriasin - A cancer associated protein

Biochemical and Biophysical Research Communications

Volumn 419, Issue 2, 2012, Pages 250-255

  Cyranka Czaja, Anna ^a   Wulhfard, Sarah ^c   Neri, Dario ^b   Otlewski, Jacek ^a  

^a UNIVERSITY OF WROC AW   (Poland)

^b ETH ZURICH   (Switzerland)

^c PHILOCHEM AG   (Switzerland)

Author keywords

Antibody fragments; Cancer marker; Phage display; Psoriasin; S100A7

Indexed keywords

ANTIBODY; ANTIGEN; PSORIASIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CELL MATURATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOLECULAR CLONING; MOLECULE; PEPTIDE LIBRARY; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION;

ANTIBODIES, NEOPLASM; ANTIBODY AFFINITY; HUMANS; NEOPLASMS; PEPTIDE LIBRARY; S100 PROTEINS; SINGLE-CHAIN ANTIBODIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84857997233     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.02.003     Document Type: Article

References (28)

1. Madsen P., Rasmussen H.H., Leffers H., Honore B., Dejgaard K., Olsen E., Kiil J., Walbum E., Andersen A.H., Basse B., et al. Molecular cloning, occurrence, and expression of a novel partially secreted protein " psoriasin" that is highly up-regulated in psoriatic skin. J. Invest. Dermatol. 1991, 97:701-712.
2. Emberley E.D., Murphy L.C., Watson P.H. S100A7 and the progression of breast cancer. Breast Cancer Res. 2004, 6:153-159.
3. Krop I., Marz A., Carlsson H., Li X., Bloushtain-Qimron N., Hu M., Gelman R., Sabel M.S., Schnitt S., Ramaswamy S., Kleer C.G., Enerback C., Polyak K. A putative role for psoriasin in breast tumor progression. Cancer Res. 2005, 65:11326-11334.
4. Emberley E.D., Niu Y., Njue C., Kliewer E.V., Murphy L.C., Watson P.H. Psoriasin (S100A7) expression is associated with poor outcome in estrogen receptor-negative invasive breast cancer. Clin. Cancer Res. 2003, 9:2627-2631.
5. Banerjee A.G., Bhattacharyya I., Vishwanatha J.K. Identification of genes and molecular pathways involved in the progression of premalignant oral epithelia. Mol. Cancer Ther. 2005, 4:865-875.
6. Ralhan R., Desouza L.V., Matta A., Chandra Tripathi S., Ghanny S., Datta Gupta S., Bahadur S., Siu K.W. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol. Cell. Proteomics 2008, 7:1162-1173.
7. Kesting M.R., Sudhoff H., Hasler R.J., Nieberler M., Pautke C., Wolff K.D., Wagenpfeil S., Al-Benna S., Jacobsen F., Steinstraesser L. Psoriasin (S100A7) up-regulation in oral squamous cell carcinoma and its relation to clinicopathologic features. Oral Oncol. 2009, 45:731-736.
8. Paruchuri V., Prasad A., McHugh K., Bhat H.K., Polyak K., Ganju R.K. S100A7 - downregulation inhibits epidermal growth factor-induced signaling in breast cancer cells and blocks osteoclast formation. PLoS ONE 2008, 3:e1741.
9. Morgan M.R., Jazayeri M., Ramsay A.G., Thomas G.J., Boulanger M.J., Hart I.R., Marshall J.F. Psoriasin (S100A7) associates with integrin β6 subunit and is required for αvβ6-dependent carcinoma cell invasion. Oncogene 2011, 30:1422-1435.
10. Silacci M., Brack S.S., Spath N., Buck A., Hillinger S., Arni S., Weder W., Zardi L., Neri D. Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng. Des. Sel. 2006, 19:471-478.
11. Villa A., Trachsel E., Kaspar M., Schliemann C., Sommavilla R., Rybak J.N., Rosli C., Borsi L., Neri D. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int. J. Cancer 2008, 122:2405-2413.
12. Pfaffen S., Hemmerle T., Weber M., Neri D. Isolation and characterization of human monoclonal antibodies specific to MMP-1A, MMP-2 and MMP-3. Exp. Cell Res. 2010, 316:836-847.
13. Askholg J., Schliemann C., Marlind J., Qureshi U., Ammar A., Pedley R.B., Neri D. Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Br. J. Cancer 2009, 101:645-657.
14. Sgier D., Zuberbuehler K., Pfaffen S., Neri D. Isolation and characterization of an inhibitory human monoclonal antibody specific to the urokinase-type plasminogen activator, uPA. Protein Eng. Des. Sel. 2010, 23:261-269.
15. Rinderknecht M., Villa A., Ballmer-Hofer K., Neri D., Detmar M. Phage-derived fully human monoclonal antibody fragments to human vascular endothelial growth factor-C block its interaction with VEGF receptor-2 and 3. PLoS ONE 2010, 5:e11941.
16. Silacci M., Brack S., Schirru G., Marlind J., Ettorre A., Merlo A., Viti F., Neri D. Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics 2005, 5:2340-2350.
17. Zakrzewska M., Krowarsch D., Wiedlocha A., Olsnes S., Otlewski J. Highly stable mutants of human fibroblast growth factor-1 exhibit prolonged biological action. J. Mol. Biol. 2005, 352:860-875.
18. Pini A., Viti F., Santucci A., Carnemolla B., Zardi L., Neri P., Neri D. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J. Biol. Chem. 1998, 273:21769-21776.
19. Honegger A., Malebranche A.D., Rothlisberger D., Pluckthun A. The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains. Protein Eng. Des. Sel. 2009, 22:121-134.
20. Worn A., Pluckthun A. Stability engineering of antibody single-chain Fv fragments. J. Mol. Biol. 2001, 305:989-1010.
21. Orr B.A., Carr L.M., Wittrup K.D., Roy E.J., Kranz D.M. Rapid method for measuring scFv thermal stability by yeast surface display. Biotechnol. Progr. 2003, 19:631-638.
22. Kortt A.A., Dolezal O., Power B.E., Hudson P.J. Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol. Eng. 2001, 18:95-108.
23. Moog-Lutz C., Bouillet P., Regnier C.H., Tomasetto C., Mattei M.G., Chenard M.P., Anglard P., Rio M.C., Basset P. Comparative expression of the psoriasin (S100A7) and S100C genes in breast carcinoma and co-localization to human chromosome 1q21-q22. Int. J. Cancer 1995, 63:297-303.
24. Emberley E.D., Alowami S., Snell L., Murphy L.C., Watson P.H. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast. Breast Cancer Res. 2004, 6:R308-315.
25. Emberley E.D., Niu Y., Leygue E., Tomes L., Gietz R.D., Murphy L.C., Watson P.H. Psoriasin interacts with Jab1 and influences breast cancer progression. Cancer Res. 2003, 63:1954-1961.
26. Ramos D.M., But M., Regezi J., Schmidt B.L., Atakilit A., Dang D., Ellis D., Jordan R., Li X. Expression of integrin β6 enhances invasive behavior in oral squamous cell carcinoma. Matrix Biol. 2002, 21:297-307.
27. Nystrom M.L., McCulloch D., Weinreb P.H., Violette S.M., Speight P.M., Marshall J.F., Hart I.R., Thomas G.J. Cyclooxygenase-2 inhibition suppresses αvβ6 integrin-dependent oral squamous carcinoma invasion. Cancer Res. 2006, 66:10833-10842.
28. Thomas G.J., Speight P.M. Cell adhesion molecules and oral cancer. Crit. Rev. Oral Biol. Med. 2001, 12:479-498.